T Le Chevalier

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. doi request reprint Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?
    T Le Chevalier
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:vii196-8. 2010
  2. ncbi request reprint Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications
    F Andre
    Departments of Medicine and Biostatistics, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 18:2981-9. 2000
  3. ncbi request reprint Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma
    K Fizazi
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94800, Villejuif, France
    Eur J Cancer 36:1514-21. 2000
  4. ncbi request reprint Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer
    L Taillade
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 18:1043-50. 2007
  5. ncbi request reprint Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma
    S Faivre
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 13:1479-89. 2002
  6. ncbi request reprint Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer
    C Monnerat
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 15:316-23. 2004
  7. ncbi request reprint Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study
    M Saghatchian
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 12:535-40. 2001
  8. ncbi request reprint Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?
    J C Soria
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 12:1667-70. 2001
  9. ncbi request reprint Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered?
    F Andre
    Department of Medicine, Gustave Roussy Institute, Villejuif, France
    Cancer 91:2394-400. 2001
  10. ncbi request reprint First-line vinorelbine-mitoxantrone combination in metastatic breast cancer patients relapsing after an adjuvant anthracycline regimen: results of a phase II study
    A Llombart-Cussac
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Oncology 55:384-90. 1998

Detail Information

Publications29

  1. doi request reprint Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?
    T Le Chevalier
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:vii196-8. 2010
    ..If these results are confirmed, tailored therapy might be the next progress for resected NSCLC...
  2. ncbi request reprint Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications
    F Andre
    Departments of Medicine and Biostatistics, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 18:2981-9. 2000
    ..We analyzed the prognosis of patients with resected N2 NSCLC to propose homogeneous patient subgroups...
  3. ncbi request reprint Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma
    K Fizazi
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94800, Villejuif, France
    Eur J Cancer 36:1514-21. 2000
    ..The efficacy/toxicity ratio of this combination compares favourably with that of our previous chemotherapy and chemo-immunotherapy regimens...
  4. ncbi request reprint Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer
    L Taillade
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 18:1043-50. 2007
    ....
  5. ncbi request reprint Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma
    S Faivre
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 13:1479-89. 2002
    ....
  6. ncbi request reprint Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer
    C Monnerat
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 15:316-23. 2004
    ..This dose-finding phase I study was designed to establish the maximum tolerated dose (MTD) of PKC412 when combined with cisplatin-gemcitabine...
  7. ncbi request reprint Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study
    M Saghatchian
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 12:535-40. 2001
    ..To evaluate the efficacy and toxicity of a chemotherapy strategy based on histological differentiation, for patients with carcinoma of unknown primary site...
  8. ncbi request reprint Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?
    J C Soria
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 12:1667-70. 2001
    ..The objective of this study was to identify patients more likely to benefit from chemotherapy in order to avoid the indiscriminate treatment of all patients...
  9. ncbi request reprint Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered?
    F Andre
    Department of Medicine, Gustave Roussy Institute, Villejuif, France
    Cancer 91:2394-400. 2001
    ..The purpose of the current study was to analyze the patterns of relapse in these patients...
  10. ncbi request reprint First-line vinorelbine-mitoxantrone combination in metastatic breast cancer patients relapsing after an adjuvant anthracycline regimen: results of a phase II study
    A Llombart-Cussac
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Oncology 55:384-90. 1998
    ..Mitoxantrone is an anthracenedione with low cardiotoxicity, and seems to be effective when combined with vinorelbine after prior exposure to anthracyclines...
  11. ncbi request reprint Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy
    K Fizazi
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 16:725-32. 1998
    ..We describe the clinical and biologic features of these patients and evaluate the results of treatment during the cisplatin era...
  12. ncbi request reprint ALIMTA (pemetrexed disodium, LY231514, MTA): clinical experience in non-small cell lung cancer
    S Novello
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Lung Cancer 34:S107-9. 2001
    ..On the basis of the results of the studies reviewed, it is clear that ALIMTA is emerging as a new drug in the management of NSCLC...
  13. ncbi request reprint Is there a standard strategy in the management of locally advanced non-small cell lung cancer?
    S Novello
    Departement of Medicine, Institut Gustave Roussy, Villejuif, France
    Lung Cancer 34:S9-14. 2001
    ..Current developments aim to optimise individual components of combined modality schedules, increase their synergism and minimise toxicity...
  14. ncbi request reprint European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancer
    S Novello
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Semin Oncol 28:3-9. 2001
    ..The use of paclitaxel in regimens without platinum and in triplet combinations is also being studied, and the optimal manner in which to administer this active agent clearly is of interest...
  15. ncbi request reprint Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen
    R Arriagada
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 13:1378-86. 2002
    ..We studied the effect of adjuvant anthracycline-based chemotherapy in postmenopausal patients with resected early breast cancer treated with adjuvant tamoxifen...
  16. ncbi request reprint Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study
    K Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 21:349-54. 2003
    ..Most patients (66%) had advanced disease. Patients received raltitrexed 3 mg/m2 followed by oxaliplatin 130 mg/m2 every 3 weeks...
  17. ncbi request reprint Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers
    T Dutu
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 16:1906-14. 2005
    ..To better define the biological characteristics of these tumors, we have compared the expression of a panel of epidermal growth factor receptor (EGFR)-related biomarkers in lung adenocarcinomas from smokers versus those in never-smokers...
  18. ncbi request reprint Developments in the treatment of early NSCLC: when to use chemotherapy
    B Besse
    Department of Oncology Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 23:x52-9. 2012
    ..If these results are confirmed, tailored therapy might be the next step forward for resected NSCLC...
  19. ncbi request reprint [Modalities of radiotherapy in small cell lung cancer: thoracic radiotherapy and prophylactic cerebral irradiation]
    C Le Pechoux
    Departement de Radiotherapie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif
    Rev Pneumol Clin 60:3S91-103. 2004
    ....
  20. ncbi request reprint Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
    T Le Chevalier
    Institute Gustave Roussy, 39 53 rue Camille Desmoulins, F 94800 Villejuif, France
    Lung Cancer 47:69-80. 2005
    ..This meta-analysis aims to quantify the treatment effect of gemcitabine plus a platinum agent in the treatment of advanced NSCLC and compare the combination to other regimens used globally...
  21. ncbi request reprint Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients
    A Auperin
    Unit of Biostatistics and Epidemiology, Radiation Oncology and Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 17:473-83. 2006
    ..Despite several randomised trials comparing radiotherapy alone with concomitant radio-chemotherapy in patients with locally advanced non-small cell lung cancer (NSCLC), it is not clear whether the addition of chemotherapy improves survival...
  22. doi request reprint Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
    J C Soria
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:2324-32. 2010
    ..In this article, we will evaluate the value of PFS as a primary measure of efficacy for advanced NSCLC, compare the clinical situation with that in other solid malignancies and review the growing number of treatment options for NSCLC...
  23. ncbi request reprint Expanding role of chemotherapy in lung cancer
    Y Loriot
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 17:x101-7. 2006
  24. pmc Ca125 and neuron-specific enolase (NSE) as tumour markers for intra-abdominal desmoplastic small round-cell tumours
    K Fizazi
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Br J Cancer 75:76-8. 1997
    ..However, normalization is frequently associated with an improvement of symptoms or a moderate clinical response...
  25. ncbi request reprint Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients
    F Griscelli
    Department of Biology, Institut Gustave Roussy, Villejuif, France
    Gene Ther 10:386-95. 2003
    ..In addition, only on the day of the injection was Ad.RSVbetagal also detected in E1-positive PBL, indicating that virus replication in blood was very unlikely...
  26. ncbi request reprint Molecular prognostic factors in resectable non-small cell lung cancer
    P Vielh
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Crit Rev Oncol Hematol 53:193-7. 2005
    ..Of special interest are some molecular factors, already or currently tested from a prognostic point of view, that might also become good candidates for predicting treatment efficacy...
  27. ncbi request reprint Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients
    R Arriagada
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 13:748-54. 2002
    ..The current analysis aimed to evaluate PCI effects on patterns of failure in this patient category...
  28. ncbi request reprint Use of chemo-radiotherapy in locally advanced non-small cell lung cancer
    S Novello
    Department of Medicine, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Eur J Cancer 38:292-9. 2002
    ..Current developments aim to optimise individual components of combined modality schedules, increase their synergism and minimise toxicity...